Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 3,386 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Pathologies Clear all

Conditions: Obesity, Abdominal, Insulin Sensitivity
Interventions: Workplace SSB sales ban, Brief Intervention; Other · Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 604 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Usher Syndrome, Retinitis Pigmentosa
Interventions: Not listed
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 0 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1999
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Liver Cancer, Metastatic Cancer
Interventions: cisplatin, doxorubicin, mitomycin, embolization; Drug · Procedure
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 37
States / cities: Fort Collins, Colorado • Jacksonville, Florida • Atlanta, Georgia + 18 more

Conditions: Acute Pain, Bunion, Abdominoplasty
Interventions: Wafermine™ 50 mg, Wafermine™ 75 mg, Placebos, Wafermine™ 25 mg; Drug
Lead sponsor: iX Biopharma Ltd.; Other
Eligibility: 18 Years to 75 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: ravuconazole; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 753 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Cardiac Arrhythmia
Interventions: Arrhythmia Management System (AMS); Device
Lead sponsor: Zoll Medical Corporation; Industry
Eligibility: 21 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 8
States / cities: Ocala, Florida • Saint Augustine, Florida • Jackson, Mississippi + 5 more

Conditions: Schizophrenia
Interventions: Inhaled Placebo, Inhaled Loxapine 5 mg, Inhaled Loxapine 10 mg; Drug
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Upland, California

Conditions: Colonic Cancer
Interventions: Aquamin®, Calcium Carbonate, Placebo; Drug
Lead sponsor: James Varani; Other
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Chronic Conditions, Multiple
Interventions: Not listed
Lead sponsor: Northeast Iowa Medical Education Foundation; Other
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Waterloo, Iowa

Conditions: Cancer
Interventions: captopril, cyclophosphamide, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Northwestern University; Other
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Nonalcoholic Steatohepatitis (NASH), Fibrosis, Liver, NAFLD
Interventions: Rencofilstat, Placebo; Drug
Lead sponsor: Hepion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 39
States / cities: Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 33 more

Conditions: Wound; Head, Multiple, Wound; Head, Scalp, Wound; Head, Wound Infection, Wound Complication, Wound Dehiscence, Wound of Skin, Wound Open, Wounds, Penetrating, Wounds, Nonpenetrating, Wounds and Injuries, Wounds, Disturbance of Wound Healing, Facial Bones Fracture, Soft Tissue Injuries, Skull Fractures, Surgical Wound, Surgical Wound Infection, Wound Healing
Interventions: Not listed
Lead sponsor: Dufresne, Craig, MD, PC; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nausea and Vomiting, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: Aprepitant, Cyclophosphamide, Dexamethasone, Granisetron hydrochloride; Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Obstructive Defecation Syndrome, Chronic Constipation, Rectocele, Intussusception
Interventions: Stapled Transanal Resection (STARR) with Transtar (PROXIMATE®) 33 mm Circular Stapler; Procedure
Lead sponsor: Ethicon Endo-Surgery; Industry
Eligibility: 21 Years to 80 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 7
States / cities: Orlando, Florida • Burlington, Massachusetts • Minneapolis, Minnesota + 3 more

Conditions: Cancer
Interventions: forodesine hydrochloride; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Tuberous Sclerosis Complex
Interventions: everolimus; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 65 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 14
States / cities: Phoenix, Arizona • Los Angeles, California • Oakland, California + 11 more

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: Lenalidomide, nab-paclitaxel; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 6 Months to 74 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 3
States / cities: Atlanta, Georgia • Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Intellectual Disability, Developmental Disability, Chronic Conditions, Multiple
Interventions: Health Research ToolKit Development; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: umbilical cord blood transplantation, Allopurinol, fludarabine phosphate, Cyclophosphamide, Total body irradiation, Treg infusion, Sirolimus; Biological · Drug · Radiation
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cancer, Pain
Interventions: Fentanyl sublingual spray; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 40
States / cities: Huntsville, Alabama • Winfield, Alabama • Glendale, Arizona + 37 more

Conditions: Multiple Sclerosis, Primary Progressive
Interventions: Fenebrutinib, Ocrelizumab, Placebo matched to ocrelizumab, Placebo matched to fenebrutinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 985 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 43
States / cities: Homewood, Alabama • Berkeley, California • Fullerton, California + 40 more

Conditions: Pain
Interventions: OrthoCor Active System; Device
Lead sponsor: Caerus Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Gulf Breeze, Florida • Detroit, Michigan • Washington Township, New Jersey + 2 more

Search by objective public record fields.

Metabolic Health Improvement Program: Effects of a Workplace Sugary Beverages Sales Ban and Motivational Counseling

Study of Dietary N-3 Fatty Acids in Patients With Retinitis Pigmentosa and Usher Syndrome

Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver

Study of Wafermine™ for Post-bunionectomy or Abdominoplasty Pain

Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

A Study of Treatment Patterns and Annualized Relapse Rate in Multiple Sclerosis Patients Who Escalate Versus Continue Disease-Modifying Therapies Following Relapse

Mobile Cardiac Telemetry and Advanced Multi-Parameter Monitoring in PatientS Wearing a Novel Device With Biometric Based Medications Changes

Staccato Loxapine in Agitation (Proof of Concept)

Aquamin and Prevention of Colon Cancer

Pharmacist and Family Medicine Physician Collaboration for Pre-Visit Planning and Team Huddles for CCM Patients

Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation

A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis

Short Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds

Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant

Study of Stapled Transanal Rectal Resection (STARR) Surgery in Refractory Constipation Associated With Obstructive Defecation Syndrome (ODS)

BCX-1777 in Treating Patients With Refractory Cancer

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma

Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

Research Engagement With People With Intellectual and Developmental Disabilities

T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer

Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

Study to Evaluate the OrthoCor Active System for Pain Relief